Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New data examines effect of inhaled corticosteroids (ICS) on survival in patients with COPD

07.11.2002


New data examines effect of inhaled corticosteroids (ICS) on survival in patients with chronic obstructive pulmonary disease (COPD)

The findings of a retrospective database study examining the effect of inhaled corticosteroids (ICS) on survival in COPD patients1 were presented today at the American College of Chest Physicians CHEST 2002 Annual Conference in San Diego.

The investigators identified male and female patients, ages 40 and older, who were enrolled in the Lovelace and Kaiser Permanente-Georgia health plans during 1995 to 2000 and who had a diagnosis of COPD. In total, 1,685 patients were identified: the ’exposed groups’ consisted of patients who had 90 days or more use of ICS (n= 786), ICS plus salmeterol (n=332) or salmeterol without ICS (n=170); the reference, or ’unexposed,’ group (n=397) were patients who had not used ICS or a long-acting beta2-agonist but had been exposed to another respiratory drug for 90 days or more.



During the study period, 28 percent of patients in the unexposed group died compared to 14 percent of patients who had been exposed to ICS and/or salmeterol. In a statistical model that controlled for age, sex, comorbid conditions, COPD severity, and asthma status and severity, exposure to either ICS (Hazard Ratio [HR] 0.59, 95% Confidence Interval [CI]: 0.46, 0.78) or salmeterol (Hazard Ratio [HR] 0.55, 95% Confidence Interval [CI]: 0.34, 0.89) were associated with a decreased risk of death. In addition, exposure to ICS plus salmeterol also reduced the risk of death (HR 0.34, 95% CI: 0.21, 0.56). In a sensitivity analysis including only those COPD patients without a history of asthma (n=840), the reduction in risk of death associated with the use of ICS plus salmeterol remained significant (HR 0.35, 95% CI: 0.17, 0.71). Use of inhaled corticosteroids was associated with longer survival in COPD patients, independent of an asthma diagnosis, age, gender, or COPD severity.

According to the CDC, approximately 24 million Americans have evidence of impaired lung function consistent with a diagnosis of COPD, the fourth leading cause of death in the US. 2 In 2000, there were 119,052 deaths from COPD. 2

COPD is a multi-component disease that includes airway inflammation, bronchoconstriction and structural changes that result in airflow obstruction. These components contribute to complex changes in lung function, symptoms and exacerbations, which affect health status and ultimately survival.

No drug has been prospectively shown to reduce mortality in COPD. It is important to note that no inhaled corticosteroid alone, or combined with a long-acting bronchodilator, is currently approved for the treatment of COPD in the US.

Serevent DiskusÒ (salmeterol inhalation powder) should be used with caution in patients with cardiovascular disorders, especially coronary insufficiency, cardiac arrthymias, and hypertension, and in patients with convulsive disorders or thytotoxicosis. Some patients may experience an increase in blood pressure or heart rate. Salmeterol should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors or tricyclic antidepressants.


Contact Robin Gaitens at 919-483-2839 for complete prescribing information for Serevent Diskus.

Sources

1. Mapel D, Roblin D, Hurley J, Davis KJ, Schreiner R, Roberts M, Frost F. Survival of COPD patients exposed to inhaled corticosteroids. Chest 2002;122(4 Suppl):74S.

2. "Chronic Obstructive Pulmonary Disease Surveillance – United States, 1971-2000," Morbidity and Mortality Weekly Report, vol. 51; No. SS-6; August 2, 2002.


Robin Gaitens | EurekAlert!

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

Im Focus: Newly proposed reference datasets improve weather satellite data quality

UMD, NOAA collaboration demonstrates suitability of in-orbit datasets for weather satellite calibration

"Traffic and weather, together on the hour!" blasts your local radio station, while your smartphone knows the weather halfway across the world. A network of...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Satellite-based Laser Measurement Technology against Climate Change

17.01.2017 | Machine Engineering

Studying fundamental particles in materials

17.01.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>